Tags
Brachytherapy, Cancer, Innovation, Investing, Isotopes, Mesh, Radiotherapy, Small-Cap, Treatment
Company Description-
IsoRay Inc. (ISR) is a company that is really doing some interesting things as of late. IsoRay as a company utilizes proprietary technologies to deliver new and different brachytherapy approaches to clinicians. Brachytherapy is a new form of radiotherapy in which radioactive materials are temporarily inserted directly into tumors or by cancerous tumors in the body. By doing this, it is ensured that the tumor receives the most effective dose of radiation to kill the cancerous cells. IsoRay is in the business of killing cancer; a business that is well supported throughout the world and will continue to see increased investment and support.
So why does IsoRay gauge my interest?
This is a company that is revolutionizing the brachytherapy business. They are creating new isotopes and ways to defeat the dreaded disease which is cancer. IsoRays Cesium-131 isotope has been dubbed as possibly “the most significant scientific advancement in cancer brachytherapy in more than 20 years.” This isotope has been used as primary treatment for prostate cancer in over 7,000 patients and is also being used as a secondary treatment method in attempting to manage non-small cell lung cancer, intra-cranial tumors, and head & neck malignancies post-surgical resection. Overall, the Cesium-131 isotope provides a powerful and new radiation treatment with a successful track record.
But really, whats so great about Cesium-131?
IsoRay as a stock has seen some heavy volatility over the last couple days due to an overly zealous initial response to great news within the recent week. On March 11th IsoRay announced that the Greek Government approved sales for a product line within the country. However, the news that probably gave way to the sudden rise was that a doctor in North Carolina successfully completed the world’s FIRST pediatric implant using IsoRay Medical’s Cesium-131 brachytherapy mesh. The patient was a 12 year old boy who had a type of childhood kidney tumor in his chest. He had been treated before for this but the cancer had returned. Not only was the operation successful, but the company was able to produce the mesh in under a week. With the use of the Cesium-131 mesh, doctors were able to get the optimal dosage to the area which they needed to reach to most effectively destroy the cancerous cells.
Stock Analysis –
After this news was spread, IsoRay saw a massive surge in its stock price, rising from a $1.09 closing price on March 18 to a closing price of 2.55 the next day. This represents an increase in price of over 130 percent. The stock also surged the next day reaching as high as $3.77 before investors brought the stock down to earth today dropping it back to about its current price of $2.50. So why will this stock be successful in the future? Well first of all as previously stated it is revolutionizing the cancer treatment industry. It has support of cancer survivors and haters everywhere and has a multitude of private investors bowing at their feet. Public investors have not been as interested due to relatively disappointing revenue numbers and growth, but companies with high research and development costs such as IsoRay often struggle to get off the ground and get their revenues higher. However, this company has been increasing its cash flows for the last couple of years and has a strong balance sheet with very low debt ratios. Growth has been slow if not negative over the last year but analysts now expect the company to grow greatly towards the end of 2014 and see massive growth in 2015.
Summary-
As a company IsoRay is increasing the size of their business and working to save the lives of millions of cancer patients around the world. Using new technologies such as their Cesium-131 isotope, they are helping to revolutionize the brachytherapy industry and improve cancer survival rates. As a stock IsoRay is likely fairly valued at about $2.50 at the current time, but as the company continues to grow and produce these innovate and novel technologies, their brand name and their stock price will grow. With a future so bright and a product that is already helping doctors to do great things, IsoRay has an extremely bright future. As a company who is revolutionizing the way we treat cancer and cancerous tumors, IsoRay is definitely ahead of the game.